Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuansong Bai

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Biochemical and Biophysical Research Communications|November 11, 2006
Successful immortalization of mesenchymal progenitor cells derived from human placenta and the differentiation abilities of immortalized cellsXiaohong Zhang, Yasushi Soda, Kenji Takahashi, et al.
Nano Letters|December 18, 2024
Dual-Targeted Drug Delivery to Myeloid Leukemia Cells via Complement- and Transferrin-Based Protein CoronaWen Wu, Yuanyuan Li, Qihui Liu, et al.
Blood|March 25, 2004
A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemiaYasushi Soda, Kenzaburo Tani, Yuansong Bai, et al.
Cancer Medicine|April 30, 2024
Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort studyAijun Liu, Hong Yu, Rui Hou, et al.
Blood|May 25, 2004
CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cellsMasamitsu Harata, Yasushi Soda, Kenzaburo Tani, et al.
JAMA|September 27, 2022
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical TrialYing Cheng, Liang Han, Lin Wu, et al.
JAMA Oncology|June 4, 2026
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical TrialJingjing Liu, Liang Han, Lin Wu, et al.
Annals of Hematology|June 6, 2024
Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trialHeng Mei, Xiaofan Liu, Yan Li, et al.
The Lancet. Respiratory Medicine|December 7, 2025
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trialLin Wang, Xuezhi Hao, Yanrong Hao, et al.
Research and Practice in Thrombosis and Haemostasis|December 10, 2025
Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trialHeng Mei, Xiaofan Liu, Yan Li, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Biochemical and Biophysical Research Communications|November 11, 2006
Successful immortalization of mesenchymal progenitor cells derived from human placenta and the differentiation abilities of immortalized cellsXiaohong Zhang, Yasushi Soda, Kenji Takahashi, et al.
Nano Letters|December 18, 2024
Dual-Targeted Drug Delivery to Myeloid Leukemia Cells via Complement- and Transferrin-Based Protein CoronaWen Wu, Yuanyuan Li, Qihui Liu, et al.
Blood|March 25, 2004
A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemiaYasushi Soda, Kenzaburo Tani, Yuansong Bai, et al.
Cancer Medicine|April 30, 2024
Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort studyAijun Liu, Hong Yu, Rui Hou, et al.
Blood|May 25, 2004
CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cellsMasamitsu Harata, Yasushi Soda, Kenzaburo Tani, et al.
JAMA|September 27, 2022
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical TrialYing Cheng, Liang Han, Lin Wu, et al.
JAMA Oncology|June 4, 2026
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical TrialJingjing Liu, Liang Han, Lin Wu, et al.
Annals of Hematology|June 6, 2024
Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trialHeng Mei, Xiaofan Liu, Yan Li, et al.
The Lancet. Respiratory Medicine|December 7, 2025
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trialLin Wang, Xuezhi Hao, Yanrong Hao, et al.
Research and Practice in Thrombosis and Haemostasis|December 10, 2025
Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trialHeng Mei, Xiaofan Liu, Yan Li, et al.
Pageof 5